CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market share analysis, 2016
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions and collaborations

3.6.2. Restraints

3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy

3.6.3. Opportunities

3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economics

CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Blood cancer

4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Lung cancer

4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Breast cancer

4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Colorectal cancer

4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Prostate cancer

4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Other cancers

4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS

5.1. Overview

5.1.1. Market size and forecast

5.2. Revlimid

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region

5.3. Avastin

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region

5.4. Herceptin

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region

5.5. Rituxan

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region

5.6. Opdivo

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region

5.7. Gleevec

5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region

5.8. Velcade

5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region

5.9. Imbruvica

5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region

5.10. Ibrance

5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region

5.11. Zytiga

5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region

5.12. Alimta

5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region

5.13. Xtandi

5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region

5.14. Tarceva

5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region

5.15. Perjeta

5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region

5.16. Other drugs

5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region

CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by application

6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe Cancer Therapeutics market, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Spain market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe market size and forecast, by application

6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. India market size and forecast, by application

6.4.2.4. Rest of Asia-Pacific

6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Latin America

6.5.2.1.1. Latin America market size and forecast, by application

6.5.2.2. Middle East

6.5.2.2.1. Middle-East market size and forecast, by application

6.5.2.3. Africa

6.5.2.3.1. Africa market size and forecast, by application

6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs

CHAPTER 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments

7.2. Astellas Pharma Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. Bristol Myers Squibb Company

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. Celgene Corporation

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance

7.5. Eli Lilly and Company

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments

7.6. F. Hoffmann-La Roche Ltd.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments

7.7. Johnson & Johnson

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments

7.8. Merck & Co., Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments

7.9. Novartis AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. Pfizer Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments